NEDA is here, it here to stay and it is evolving. #MSBlog #MSResearch
"As promised; my platform presentation from yesterday. It is clear that treat-2-target is getting a lot of attention at this meeting as well as end-organ damage. There was a prestentation yesterday by Professor Ludwig Kappos to try and incorporate brain atrophy into the measurement; i.e. NEDA-4. This indicates that NEDA is behaving the way it should an evolving over time."
Labels: dimethylfumarate, DMF, ECTRIMS 2014, NEDA